Background:          The purpose of this study was to correlate the evaluation of BRAF V600E by IHC and RT–PCR to correctly categorize, prognosticate and offer the best possible treatment for the serous ovarian tumors thus contributing an attempt for better patient survival and quality of life.

Aims:      To study the expression of BRAF mutation by Immunohistochemistry (IHC) and Real Time Polymerase Chain Reaction (RT–PCR) in various histological grades of serous ovarian tumors

Study design:        This cross section observational study was performed in thirty cases of serous ovarian tumors to access expression of BRAF mutation

Subjects & methods:            To correlate histomorphological grades of serous ovarian tumors with immunohistochemical and RT–PCR results of BRAF mutation in 30 cases.

Statistical Analysis Used: The correlation between BRAF scoring by IHC & RT–PCR, WHO histological grade and subtype of tumor was assessed using Pearson Chi Square Test with statistically significant p–value < 0.05

Results: This study confirmed the higher frequency of BRAF V600E mutations in benign serous tumors, than in high grade tumors as assessed by both IHC and RT–PCR, however no statistically significant correlation could not established between them. It is therefore suggested that the study to be continued with larger number of cases and as a multicentric project with clinical follow–up to comprehend the different facets of BRAF pathway in ovarian neoplasms.